Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas N, Harshman L, Quinn D, Larkin J, Pal S, Powles T, Ryan C , Sternberg C, Uzzo R, Choueiri T , Bex A.

Eur Urol. 2018 May 18.[Epub ahead of print]


Context: Contradictory data exist with regard to adjuvant vascular endothelial growth
factor receptor (VEGFR)-targeted therapy in surgically managed patients for localized
renal cell carcinoma (RCC).
Objective: To systematically evaluate the current evidence regarding the therapeutic
benefit (disease-free survival [DFS] and overall survival [OS]) and grade 3–4 adverse
events (AEs) for adjuvant VEGFR-targeted therapy for resected localized RCC.
Evidence acquisition: A critical review of PubMed/Medline, Embase, and the Cochrane
Library in January 2018 according to the Preferred Reporting Items for Systematic
Review and Meta-Analysis (PRISMA) statement was performed. We identified reports
and reviewed them according to the Consolidated Standards of Reporting Trials and
Standards for the Reporting of Diagnostic Accuracy Studies criteria. Of eight full-text
articles that were eligible for inclusion, five studies (two of five were updated analyses)
were retained in the final synthesis. Study characteristics were abstracted and the
number needed to treat (NNT) per trial was estimated.

Read on: Eur Urol. 2018 May 18.[Epub ahead of print]

More from the InfoHUB